Advertisement
Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

CDS Software Control

April 21, 2011 6:59 am | Product Releases | Comments

Thermo Fisher Scientific Inc., announced the availability of a new Thermo Scientific Atlas Chromatography Data System (CDS) instrument control software for the Shimadzu Prominence and Prominence XR HPLC.

TOPICS:

SPE Methods Development Web Tool

April 21, 2011 6:42 am | Product Releases | Comments

Phenomenex Inc. introduces the Solid Phase Extraction (SPE) Method Development Tool, an online resource that develops methods across a variety of sample matrices and compounds.

TOPICS:

Interactive Workspace

April 20, 2011 8:16 am | Product Releases | Comments

Chemical Abstracts Service introduced SciPlanner, an interactive workspace that enables scientists to more quickly identify synthesis options for designing the best research pathways and approaches.

TOPICS:
Advertisement

Wireless Monitoring

April 20, 2011 8:13 am | Product Releases | Comments

Thermo Fisher Scientific Inc. introduced its Smart-Vue wireless monitoring solution. Smart-Vue protects precious samples by monitoring key laboratory parameters including temperature, CO2 concentration, humidity and differential pressure.

TOPICS:

Gilead And Microdose Announce Collaboration

April 20, 2011 8:02 am | News | Comments

Gilead Sciences, Inc. and MicroDose Therapeutx, Inc. announced that the companies have entered into an exclusive worldwide license and collaboration agreement for the development and commercialization of MDT-637.

TOPICS:

Cumberland Pharma Buys Rights to Drug Candidate

April 20, 2011 7:58 am | News | Comments

Cumberland Pharmaceuticals Inc. said it acquired the rights to a molecule named ifetroban and will test it as a potential in-hospital treatment for a condition that involves progressive kidney failure.

TOPICS:

Decoding Cancer Patients' Genomes A Powerful Tool

April 20, 2011 7:55 am | News | Comments

Two new studies highlight the power of sequencing cancer patients' genomes as a diagnostic tool, helping doctors decide the best course of treatment and researchers identify new cancer susceptibility mutations that can be passed from parent to child.

TOPICS:

First Patient Treated in CicloMulsion Trial

April 20, 2011 7:52 am | News | Comments

NeuroVive Pharmaceutical and Hospices Civils de Lyon has dosed the first of 1,000 enrollees in its phase 3 trial of CicloMulsion for patients undergoing PCI for acute myocardial infarction to examine cyclosporine's ability to protect cardiac tissue.

TOPICS:
Advertisement

Anavex Begins Alzheimer’s Trial

April 20, 2011 7:38 am | News | Comments

Anavex Life Sciences Corp. announced that the first healthy human volunteers have been initially dosed in its Phase 1 clinical trial to evaluate ANAVEX 2-73, the company’s lead compound for Alzheimer’s disease.

TOPICS:

Forest Profits Up Over $322M

April 20, 2011 7:27 am | News | Comments

Forest Laboratories Inc. said its net income jumped in the fiscal fourth quarter compared to last year, when it made a large payment to AstraZeneca PLC to get the rights to a potential antibacterial drug cocktail.

TOPICS:

Abbott Profit Falls 14% on Charges

April 20, 2011 7:25 am | News | Comments

Drug and medical device maker Abbott Laboratories said its first-quarter net income fell 14 percent on restructuring and acquisition costs and other expenses. For the period ended March 31, the company earned $864 million, or 55 cents per share.

TOPICS:

Decoding Genes with the Help of Open-Source Encyclopedia

April 20, 2011 7:22 am | News | Comments

A massive database cataloging the human genome's functional elements—including genes, RNA transcripts, and other products—is being made available as an open resource to the scientific community, classrooms, science writers, and the public.

TOPICS:

New Study Shows High Incidence of Virological Failure

April 20, 2011 7:17 am | News | Comments

A study of European HIV-positive children shows that 12% of children (around 1 in 8) develop triple-class virological failure by 5 years after starting their antiretroviral drug treatment program.

TOPICS:

Targeting IL-6 to Halt Breast, Prostate Cancer

April 20, 2011 7:14 am | News | Comments

An Ohio State biophysicist used a supercomputer to search thousands of molecular combinations for the best configuration to block a protein that can cause breast or prostate cancer.

TOPICS:

Using Stress To Detonate Cancer Cells

April 20, 2011 6:59 am | News | Comments

Researchers have found a new way to force cancer cells to self-destruct. Low doses of an anti-cancer drug currently in development sensitizes tumor cells to a second drug, called TRAIL, also being developed as a cancer treatment.

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading